<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Systemic administration of α2-<z:chebi fb="0" ids="37886">adrenergic agonists</z:chebi> has been shown to protect ischemic myocardium, but the direct effects on <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfused myocardium have not yet been clarified </plain></SENT>
<SENT sid="1" pm="."><plain>This study was carried out to determine the effects of intracoronary <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi> (DEX) on the <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>-reperfusion injury in anesthetized pigs </plain></SENT>
<SENT sid="2" pm="."><plain>In open-chest pigs, the left anterior descending coronary artery was perfused through an extracorporeal circuit from the carotid artery </plain></SENT>
<SENT sid="3" pm="."><plain>They received intracoronary infusion of DEX at a rate of 1 ng · mL(-1) (group LD, n = 9), 10 ng · mL(-1) (group MD, n = 9), or 100 ng · mL(-1) (group <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, n = 9) of coronary blood flow or vehicle (group C, n = 12) for 30 min before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0206146" disease_type="Disease or Syndrome" abbrv="">Myocardial stunning</z:e> was produced by 12-min <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> of the perfused area of left anterior descending coronary artery and 90-min reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>The effect on reperfusion-induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> was evaluated using the incidence of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> or <z:mp ids='MP_0006109'>fibrillation</z:mp> after reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>Regional myocardial contractility was evaluated with segment shortening (%SS) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="4466">Dexmedetomidine</z:chebi> significantly reduced the incidence of reperfusion-induced <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="4466">Dexmedetomidine</z:chebi> significantly improved the recovery of percentage segment shortening at 90 min after reperfusion (32.6% ± 3.1% in group C, 58.2% ± 2.1% in group LD, 61.1% ± 1.8% in group MD, and 72.0% ± 2.0% in group <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="4466">Dexmedetomidine</z:chebi> suppressed the increase in plasma <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> concentration after reperfusion </plain></SENT>
<SENT sid="10" pm="."><plain>The results indicate that DEX would exert the protective effect against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion injury by the direct action on the myocardium, which is not mediated through the central <z:mp ids='MP_0008912'>nervous</z:mp> system </plain></SENT>
</text></document>